Sign up for email updates
Bookstore

Arthritis

Back Pain & Osteoporosis
Coronary Heart Disease
Depression & Anxiety
Diabetes
Digestive Disorders
Heart Attack Prevention
Hypertension & Stroke
Lung Disorders
Memory
Nutrition & Weight Control
Prostate Disorders
Vision


Prostate Disorders

From the Current Issue

New Research:
Study Finds Long-Term Benefits With Finasteride Treatment

Men with BPH who take finasteride (Proscar) are at reduced risk for acute urinary retention (AUR) and are less likely to require surgery to treat the condition, according to six-year results from the Proscar Long-Term Efficacy and Safety Study (PLESS).

The current study is an extension of a four-year trial of more than 3,000 BPH patients who were randomly assigned to 5 mg of finasteride daily or a placebo. In the four-year trial, patients on the drug had a 57% lower risk of developing AUR compared with men taking a placebo, and were 55% less likely to require surgery to treat BPH symptoms.

After the four years, participants on the placebo were given the option of switching to finasteride. Two years later, results with more than 2,400 men found that those who had taken finasteride for six years continued to have lower rates of AUR and BPH surgery than those taking a placebo. Those who switched to finasteride had reductions in AUR and BPH surgery that approached levels found in the men who had taken the drug long term.

The researchers concluded that “finasteride treatment led to a sustained decrease in the incidence of AUR and/or BPH–related surgery.”

 

The Journal of Urology
Volume 171, page 1194
March 2004


 

PROSTATE BULLETIN
The PROSTATE BULLETIN is a quarterly publication that presents the latest treatment information available to help you take charge of your medical care for prostate disease.
Subscribe now

 


Buy now

2005
WHITE PAPERS
Prostate Disorders

The prostate disorders White Paper from The Johns Hopkins White Papers series is an annual, in-depth report written by Hopkins physicians.

 

 

    Contact us 
    © 2005 Medletter Associates, Inc.